Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
49 hedge funds and large institutions have $231M invested in Allena Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
26% more capital invested
Capital invested by funds: $183M → $231M (+$48.2M)
17% more funds holding
Funds holding: 42 → 49 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.85M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.98M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.74M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.91M |
| 5 |
Millennium Management
New York
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.97M |
| 2 |
PIM
Partner Investment Management
San Francisco,
California
|
-$4M |
| 3 |
PI
Pharmstandard International
Luxembourg
|
-$2.29M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.06M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.14M |
ALNA Hedge Fund Activity: Q2 2018 in Review
49 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2018, worth a combined $231M — up 26% from $183M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALNA positions and 5 closed out — a net gain of 7 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $4.85M. The largest seller was Fidelity Investments, cutting an estimated $4.97M.
- 49 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2018, up from 42 in Q1 2018.
- Funds reported $231M of Allena Pharmaceuticals stock for Q2 2018, up 26% quarter-over-quarter.
- 12 funds opened new Allena Pharmaceuticals positions in Q2 2018 and 5 closed out, a net change of +7 holders.
- The largest Allena Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $4.85M added.
- The largest Allena Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $4.97M sold.
Based on aggregated 13F filings for Q2 2018.